Comparative tolerability of the newer fluoroquinolone antibacterials
about
Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trialsReversible craniocervical dystonia associated with levofloxacin.Cardiotoxicity of fluoroquinolonesPharmacometabolomic approach to predict QT prolongation in guinea pigsA New Structure-Activity Relationship (SAR) Model for Predicting Drug-Induced Liver Injury, Based on Statistical and Expert-Based Structural AlertsMoxifloxacin-induced Clostridium difficile-associated diarrhea.ADDME--Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspectiveEfficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review.Clinical pharmacology of gatifloxacin, a new fluoroquinolone.A review of clinical trials with fluoroquinolones with an emphasis on new agents.Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections.Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.New milestones achieved in fluoroquinolone safety.Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features.A rare case of ciprofloxacin-induced bilateral rupture of the Achilles tendon.Use of anti-infective agents during lactation: Part 2--Aminoglycosides, macrolides, quinolones, sulfonamides, trimethoprim, tetracyclines, chloramphenicol, clindamycin, and metronidazole.Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case reportHepatic safety of antibiotics used in primary careTreatment of inflammatory bowel disease in childhood: best available evidence.Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects.Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections.Safety of fluoroquinolones in paediatrics.Current therapy of ulcerative colitis in children.Ofloxacin Induced Cutaneous Reactions in Children.Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study.Safety of fluoroquinolones: An updateCutaneous adverse events and gemifloxacin: observations from the clinical trial program.Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones.Carbapenems: a potent class of antibiotics.Death following bilateral complete Achilles tendon rupture in a patient on fluoroquinolone therapy: a case report.Assessment of the dermal and ocular irritation potential of lomefloxacin by using in vitro methods.Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires extracellular signal-regulated kinase and c-Jun N-Terminal Kinase.Use of the respiratory fluoroquinolones for the outpatient management of community-acquired pneumoniaHepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages.Fluoroquinolone-induced liver injury: three new cases and a review of the literature.Comparison of Pathogen Eradication Rate and Safety of Anti-Bacterial Agents for Bronchitis: A Network Meta-Analysis.The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.Levofloxacin-induced acute psychosis.Amoxillin- and pefloxacin-induced cholesterogenesis and phospholipidosis in rat tissues.
P2860
Q24653970-C9AAC234-D5A7-4EA6-9AD1-F51254034A1BQ27315854-FB77EC79-BE4D-4F88-86F3-609F788B1E66Q28209298-1D4E383F-FF43-4853-8F01-4A2622EDF2E6Q28485993-8DBC7CC2-679C-441C-BC1B-8BFC61EBCCD6Q28820944-BDDCC4D4-1048-459D-8F82-376FB9ED3543Q33357639-240D4C45-9242-4014-9864-C30322D6648FQ33469822-0D0F0365-EF85-4CE8-82E2-755CC14358B0Q33739099-E013177A-FDE6-4753-B80E-7C1DA2C9C1A1Q34030783-75FE5D71-036D-467C-BA74-2308C5216970Q34074724-BBB7F5E2-72E9-4A85-A1E6-7FD9BAF564EEQ34141064-DA76BC09-D676-485A-8DBE-2C860518EB74Q34186776-CC92A8A4-1BA4-4AD7-84E3-0B347BD7F4A3Q34186786-F9C7B975-6E62-47DE-9A89-05238E6FAFCEQ34240856-F168562A-45BE-432C-BE24-4A6980FFA310Q34526517-A13C0DD2-D348-4259-A85F-52468E224888Q34533754-BFF8447C-5D63-45B8-AC56-146E5AF3EFC7Q35024655-50DF8E27-3BBC-4CAA-94F6-2D8246912B5EQ35037383-17256023-6795-494B-91D3-4DAC1F2EB999Q35091746-BCAB64AF-8AFE-4FE4-A3D3-FE4284630625Q35102747-D62A566E-4A75-4D77-8187-F5F8AA693DD6Q35164756-E710CEF9-F7C9-4ADE-A1BD-733ED4637929Q35194456-E15EBBDC-92B3-4480-A9CF-889670764246Q35609674-34E2B40D-C6CD-488F-9BE7-5D1748186010Q35918110-DEE98091-F8AC-4CD5-BFE1-FAD2138CB695Q36131710-C28E5B64-4980-48E8-90F7-400D6891826EQ36170467-F210F504-EE08-46D1-B8FA-20C37BC47531Q36435461-6F1331B1-F4F4-4555-9ED4-35E03FD2AF30Q36825816-62B812B8-A4FF-4271-B583-6605108C08ACQ37030838-9B498D06-F9FA-4F25-8087-ADCCC10CEDDEQ37074265-5A44B23A-5502-4F3B-A81A-ED1163176D78Q37326542-ADEE1047-FBA1-4FD7-946D-5486AA819871Q37707739-132829C0-A42E-4AC3-BA55-259CB86EB5BDQ37719126-3E5A6182-BE3E-48E2-A502-29607700B635Q37724173-7916F16E-F394-4487-BA1C-BCA034AF9A6EQ37975927-6F687D0C-1622-45E2-BC42-5966B6D0BBA4Q38946549-A57A2BC3-D640-4E48-9F62-36CC616A264FQ40636919-E0DD61ED-F697-45DB-AF95-6BE62DEEF517Q41098625-A0CE7953-3271-4387-ADA4-3A552834352AQ41790716-F9F905D6-589D-4B79-8D75-71AC8FA27F02Q42145880-98623658-E4D4-4A63-A894-1558A1128D9A
P2860
Comparative tolerability of the newer fluoroquinolone antibacterials
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Comparative tolerability of the newer fluoroquinolone antibacterials
@ast
Comparative tolerability of the newer fluoroquinolone antibacterials
@en
Comparative tolerability of the newer fluoroquinolone antibacterials
@nl
type
label
Comparative tolerability of the newer fluoroquinolone antibacterials
@ast
Comparative tolerability of the newer fluoroquinolone antibacterials
@en
Comparative tolerability of the newer fluoroquinolone antibacterials
@nl
prefLabel
Comparative tolerability of the newer fluoroquinolone antibacterials
@ast
Comparative tolerability of the newer fluoroquinolone antibacterials
@en
Comparative tolerability of the newer fluoroquinolone antibacterials
@nl
P2093
P1433
P1476
Comparative tolerability of the newer fluoroquinolone antibacterials
@en
P2093
P304
P356
10.2165/00002018-199921050-00005
P407
P577
1999-11-01T00:00:00Z
P6179
1005870341